These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3012292)

  • 1. Protection of mice against herpes simplex virus infection by a Lactobacillus casei preparation (LC 9018) in combination with inactivated viral antigen.
    Watanabe T; Saito H
    Microbiol Immunol; 1986; 30(2):111-22. PubMed ID: 3012292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary resistance induced in mice by Lactobacillus casei following infection with herpes simplex virus.
    Watanabe T; Yamori T
    Kansenshogaku Zasshi; 1989 Mar; 63(3):182-8. PubMed ID: 2475554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence.
    Hilfenhaus J; Christ H; Köhler R; Moser H; Kirchner H; Levy HB
    Med Microbiol Immunol; 1981; 169(4):225-35. PubMed ID: 6268955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage extrinsic antiviral activity during herpes simplex virus infection.
    Morahan PS; Morse SS; McGeorge MG
    J Gen Virol; 1980 Feb; 46(2):291-300. PubMed ID: 6247426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
    Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
    Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.
    Chan WL; Lukig ML; Liew FY
    J Exp Med; 1985 Oct; 162(4):1304-18. PubMed ID: 2995536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between increase in Ia-bearing macrophages and induction of T cell-dependent antitumor activity by Lactobacillus casei in mice.
    Kato I; Yokokura T; Mutai M
    Cancer Immunol Immunother; 1988; 26(3):215-21. PubMed ID: 3133111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2.
    Hazama M; Mayumi-Aono A; Miyazaki T; Hinuma S; Fujisawa Y
    Immunology; 1993 Apr; 78(4):643-9. PubMed ID: 8388365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of "modified-self"-induced specific antibody hyporesponsiveness to herpes simplex virus.
    Wilson LA; Thompson JJ; Ohkawa S; Scott DW
    Viral Immunol; 1992; 5(2):113-22. PubMed ID: 1377470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo release of cytostatic factors from Lactobacillus casei-elicited peritoneal macrophages after stimulation with tumor cells and immunostimulants.
    Hashimoto S; Nomoto K; Nagaoka M; Yokokura T
    Cancer Immunol Immunother; 1987; 24(1):1-7. PubMed ID: 3102062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations.
    Ertürk M; Jennings R; Hockley D; Potter CW
    J Gen Virol; 1989 Aug; 70 ( Pt 8)():2149-55. PubMed ID: 2769234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of immunologic resistance to herpes simplex virus 1 (HSV-1) infection.
    Rager-Zisman B; Allison AC
    J Immunol; 1976 Jan; 116(1):35-40. PubMed ID: 173758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of OK-432, a Streptococcus pyogenes preparation, against lethal infection of mice with herpes simplex virus.
    Harada Y; Kurokawa E; Endo H; Kimura T; Saito M; Sugawara Y; Irie H; Ito K; Fujii M; Shimizu Y
    Microbiol Immunol; 1989; 33(6):467-77. PubMed ID: 2549347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2.
    McDermott MR; Brais LJ; Evelegh MJ
    J Gen Virol; 1990 Jul; 71 ( Pt 7)():1497-504. PubMed ID: 2165134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.
    Kitces EN; Morahan PS; Tew JG; Murray BK
    Infect Immun; 1977 Jun; 16(3):955-60. PubMed ID: 197013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
    Roberts PL; Duncan BE; Raybould TJ; Watson DH
    J Gen Virol; 1985 May; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice.
    El-Ghorr AA; Williams RM; Heap C; Norval M
    FEMS Immunol Med Microbiol; 2000 Dec; 29(4):255-61. PubMed ID: 11118905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yeast-derived glycoprotein B-1 of herpes simplex virus (HSV) as a candidate for an HSV vaccine.
    Kino Y
    Adv Exp Med Biol; 1990; 278():183-90. PubMed ID: 1963033
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization and immunogenicity of HSV-1 antigens obtained following zwitterionic detergent treatment.
    Mukhlis FA; Jennings R; Stephenson TJ; Quasim T; Potter CW
    Vaccine; 1986 Sep; 4(3):191-6. PubMed ID: 3020821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.